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Introduction:  Countries  like  Vietnam  transitioning  to  middle-income  status  increasingly  bear  the  cost  of
both existing  and  new  vaccines.  However,  the  impact  and  cost-effectiveness  of the  Expanded  Programme
on  Immunization  (EPI)  as a whole  has  never  been  assessed  on a  country  level.
Methods: Data  on vaccine-preventable  disease  incidence  and  mortality  from  Vietnam’s  national  surveil-
lance was  analysed  to  estimate  the  likely  impact  that  vaccination  in  1980–2010  may  have  had.  Adjustment
for  under-reporting  was  made  by examining  trends  in  reported  mumps  incidence  and  in  case-fatality
risks  for each  disease.  The  same  data  were  separately  analysed  using  the  Lives  Saved  Tool  (LiST)  to give
an alternative  estimate  of impact.  The  ﬁnancial  cost  of EPI  in 1996–2010  was  also  estimated  from  the
perspective  of service  provider.
Results:  National  surveillance  data  suggests  that  up  to  5.7 million  diseases  cases  and 26,000  deaths  may
have  been  prevented  by EPI.  Analysis  using  LiST  suggests  that  even  more  deaths  (370,000)  may  have  been
prevented  by measles  and  pertussis  vaccination  alone.  The  cost-effectiveness  of  EPI  is estimated  to  be
around  $1000–$27,000  per death  prevented.
Conclusion:  Two  separate  approaches  to assessing  EPI  impact  in Vietnam  give  different  quantitative  results
but a  common  conclusion:  that EPI  has  made  a  substantial  impact  on  mortality  and  represents  good  value
for money.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/3.0/).. IntroductionThe Expanded Programme on Immunization (EPI) was  estab-
ished by the World Health Organization (WHO) in 1974 to
upport countries in increasing uptake of vaccines against measles,
Abbreviations: DALY, disability adjusted life year; DPT, diphtheria–pertussis–
etanus vaccine; EPI, Expanded Programme on Immunization; LiST, Lives Saved Tool.
∗ Corresponding author at: Modelling and Economist Unit, Public Health England,
1  Colindale Avenue, London NW9  5EQ, UK. Tel.: +44 0 20 8327 7803;
ax: +44 0 20 8200 7868.
E-mail address: mark.jit@phe.gov.uk (M.  Jit).
ttp://dx.doi.org/10.1016/j.vaccine.2014.12.017
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article udiphtheria, pertussis, tetanus, poliomyelitis and tuberculosis.
Between 1980 and 2011, global coverage of the third dose of
diphtheria–pertussis–tetanus vaccine (DPT) increased from 20% to
83%, while that of measles-containing vaccine increased from 16%
to 85% [1].
A World Bank report [2] considered that vaccines covered by
EPI are among the most cost-effective interventions available, with
measles immunization estimated to cost $10 per disability life year
(DALY) prevented, and DPT immunization $25 per DALY prevented.
A more recent analysis [3] suggested that the incremental cost per
death averted of EPI ranges from $274 in South Asia to $1754 in
Europe and Central Asia in 2001 US$, and is about $478 in East
Asia and the Paciﬁc. However, the impact and cost-effectiveness
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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f the EPI vaccine package has never been formally evaluated on
 national level. Hence previous cost-effectiveness analyses have
elied on extrapolation of limited data to a global level.
A key indicator of EPI success is observed reductions in vaccine-
reventable disease incidence and mortality [4]. However, passive
urveillance of trends in disease incidence may  be affected by
nderreporting, particularly of cases that do not present for health
are. Furthermore, the degree of underreporting may  change over
ime as case deﬁnitions, access to care and surveillance systems
volve. On the other hand, active surveillance methods such as
ross-sectional surveys without major sources of bias are normally
oo resource-intensive to be conducted regularly in low and middle
ncome countries. For mortality, establishing the cause of death is
ifﬁcult when symptoms are non-speciﬁc and children have mul-
iple co-morbidities at the time of death. Lastly, even if declines in
evere disease and mortality are well-documented, these may  be
ue to improved access to care, nutrition and general health as well
s vaccination.
EPI was ﬁrst introduced in Vietnam in 1981, and became
ne of six national targeted health programmes in 1985. The
rogramme originally vaccinated infants against six diseases (diph-
heria, tetanus, pertussis, poliomyelitis, measles, and tuberculosis).
y 2009, 96% of children less than 1 year old were recorded as hav-
ng received three doses of DPT. EPI’s successes include elimination
f polio in 2000 and of maternal and neonatal tetanus in 2005.
Vietnam has beneﬁtted from Gavi support for vaccine intro-
uction and health systems strengthening, but eligibility for these
unds may  end as Vietnam transitions to middle-income status.
ence both the current EPI as well as new vaccine introductions
ill be increasingly funded by national resources. Yet there are
ompeting priorities for Vietnam’s public investments both within
nd outside the health sector. As the government plans for future
nvestments, it is critical to understand the impact and value of
ietnam’s EPI.
The goal of this study is to assess the impact and cost-
ffectiveness of Vietnam’s EPI in reducing mortality and morbidity
ssociated with vaccine-preventable diseases over its 30 year his-
ory. The study addresses a key evidence gap in providing the ﬁrst
ational impact and economic evaluation of EPI. To do so, two com-
lementary methods were used. First, data on vaccine-preventable
isease incidence and mortality from national surveillance were
nalysed to estimate the likely impact that 30 years of vaccina-
ion may  have had. Second, the Lives Saved Tool (LiST) was used.
iST is a model to estimate the number of lives saved by different
ackages and coverage levels of health interventions by combining
vidence about the effectiveness of maternal, neonatal and child
ealth interventions with country speciﬁc information about cause
f death and current coverage of health interventions.
. Methods
.1. Statistical modelling based on surveillance data
The National Institute of Hygiene and Epidemiology records
otiﬁcations of cases and deaths attributed to measles, diphtheria,
ertussis, tetanus and polio in 1980–2010 in all ages. Surveillance
as based on clinical, epidemiological and microbiological con-
rmation for polio (since 1992) and measles (since 2000), and
linical diagnosis only for other diseases. Case deﬁnitions are given
n Appendix A.1; these were unchanged over the entire period
980–2010, apart from a change in the measles case deﬁnition in
003 by which time measles incidence had reached very low levels.
Decreases in notiﬁed cases give an indication of the impact of
accination. However, incidence may  have declined due to reasons
nrelated to vaccination, such as changes in case ascertainment(2015) A233–A239
and disease risk factors. To control for non-vaccine related changes,
annual vaccine-preventable disease notiﬁcations were adjusted
based on changes in mumps  incidence in the same year (see
Appendix A.3). Mumps  was  chosen as a control variable because
there is no mumps  vaccination programme currently in place in
Vietnam, so any changes in reported mumps incidence must be
due to non-vaccine related causes. A regression curve was ﬁtted
to annual mumps  incidence to smooth out year-to-year variations
(see Appendix A.2).
The National Institute of Hygiene and Epidemiology records
administrative coverage for measles, DPT and polio vaccines in
1980–2010, except for 1988. Reported incidence for measles, diph-
theria, pertussis and polio was related to routine dose coverage in
order to investigate the temporal association between increasing
vaccine coverage and decreasing disease incidence (hence provid-
ing evidence that vaccination is a cause of disease decline). Tetanus
was not modelled since reductions in neonatal tetanus incidence
are not easily associated with infant DPT vaccination alone, and
are due also to maternal vaccination. For parsimony, coverage of
catch-up, second dose and booster programmes was  not consid-
ered; these programmes took place in the latter years of the period
1980–2010 when disease incidence had already reached fairly low
levels. Twelve linear regression models were used to explore the
association between incidence (with or without the mumps adjust-
ment factor) and vaccine coverage over the past three years (see
Table 1). The reduction in disease incidence attributed to vaccina-
tion in a particular year was assumed to be equal to the difference
between incidence in that year estimated by each model (unless
this was negative, in which case it was rounded to zero) and inci-
dence predicted to occur by the same model when vaccine coverage
was 0%. Models giving the largest and smallest estimated number of
vaccine-prevented deaths were selected to provide an uncertainty
range. If notiﬁcation data alone or mumps-adjusted notiﬁcation
data (without regression modelling) gave the largest or smallest
number this was  selected instead.
The number of deaths attributed to vaccine-preventable dis-
eases may  have declined due to reasons unrelated to vaccination,
such as improved healthcare and nutrition. To adjust for this, it
was assumed that reductions in deaths due to reasons unrelated to
vaccination reduced the case-fatality risk of disease without affect-
ing disease incidence. On the other hand, vaccination is assumed
to simply prevent disease from occurring in the ﬁrst place, rather
than to reduce the severity (and hence risk of death) of cases. Hence
the number of deaths prevented by vaccination in a particular year
was assumed to be the estimated number of disease cases pre-
vented by vaccination in that year (as described above), multiplied
by the case-fatality risk for the disease in that year estimated using
national surveillance data (see Appendix A.5 for equations).
2.2. Estimation of the number of deaths prevented using the Lives
Saved Tool (LiST)
LiST was used to model under-ﬁve mortality due to measles and
pertussis in 1980–2010. Polio and diphtheria have limited roles in
under-ﬁve mortality while neonatal pertussis is not directly pre-
vented by infant vaccination alone. Details of LiST methodology
have been published elsewhere [5]. Brieﬂy, a complete LiST pro-
jection was  constructed for 2000 using all coverage data, health
status information and mortality rates. The 1980 coverage and
health status rates were entered for the years 2001–2005 in
order to extrapolate the most likely proportionate cause of death
in neonates and 1–59 months olds using a method previously
reported in the literature [6]. These values were then used in the
baseline LiST projection for the years 1980–2010. Full details of data
sources and methodology are given in Appendix A.6.
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Table  1
Linear regression models used to relate disease incidence to vaccine coverage. Symbols: xi = incidence of notiﬁed cases in year i, yi = incidence of notiﬁed cases in year i
adjusted using mumps data, ci = vaccine coverage in year i (ci = 0 for i < 1980).
Model number Model equation Dependent variable Independent variable(s)
Disease
incidence xi
Mumps-adjusted
disease incidence yi
Vaccine
coverage in the
same year ci
Vaccine coverage
in the previous
year ci−1
Vaccine
coverage two
years ago ci−2
1 xi ∼ ci √ √
2  xi ∼ ci + ci−1 √ √ √
3  xi ∼ ci + ci−1 + ci−2 √ √ √ √
4  xi ∼ ci + ci−2 √ √ √
5  xi ∼ ci−1 √ √
6  xi ∼ ci−1 + ci−2 √ √ √
7  yi ∼ ci . √ √
8  yi ∼ ci + ci−1 √ √ √
9  yi ∼ ci + ci−1 + ci−2 √ √ √ √√ √ √
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T10  yi ∼ ci + ci−2
11  yi ∼ ci−1 √ 
12  yi ∼ ci−1 + ci−2 √ 
The LiST analysis was compared to the reduction over time in
he number of cases of and deaths due to measles and pertussis
in 1980–2010) according to national surveillance data. To do this,
he average annual number of cases and deaths between 1980 and
986 was calculated and compared to the average annual value
etween 2000 and 2010, for both measles and pertussis, to calculate
 percent reduction over time.
.3. EPI costs
The ﬁnancial cost of Vietnam’s EPI in 1996–2010 was estimated
rom the perspective of the service provider. Records prior to 1996
including start-up costs) were not available. All the inputs (ingre-
ient) used in implementing the programme were captured. The
ost per vaccine dose was estimated by incorporating all rele-
ant ingredients, such as personnel, supplies, vaccine procurement,
perations and logistics (see Appendix A.7). The total annual cost
f each vaccine was estimated by multiplying the average cost per
ose by the total number of doses used by the program in that year.
osts were presented in 2010 US$.
. Results
Models relating notiﬁcations incidence and vaccine coverage for
ach of the four diseases appear to ﬁt data well, based on visual
nspection and by comparing their Akaike Information Criterion
see Appendix A.4 for results). They capture initial high disease
ncidence prior to vaccination as well as its rapid decline as EPI
as rolled out nationally. Coefﬁcients relating disease notiﬁcations
o vaccine coverage were negative (including the entire 95% con-
dence interval; data not shown), supporting the hypothesis that
accination has been a cause of disease decline. Models predict a
pike in diphtheria and pertussis incidence around 2002 which did
ot occur in practice, despite a sharp decline in DPT coverage from
6% in 2001 to 75% in 2002. The reason for this may be herd pro-
ection from existing vaccinated cohorts; these indirect effects are
oorly captured by a linear model [7]. The best ﬁtting model was
odel 11 for polio, and model 9 for all other diseases.
Case-fatality risks for measles, pertussis, diphtheria and polio
eclined in 1980–2010 (Fig. 1). Temporary increases in 1993
measles), 2005 (pertussis) and 1990–1996 (polio) may  represent
utbreaks in socioeconomically disadvantaged areas with a higher
ase-fatality risk, due to lower vaccine coverage in these geograph-
cally restricted regions. High reported case-fatality risk for polio
n the decade prior to elimination may  reﬂect improved ascertain-
ent of polio deaths due to the attention being given to this disease.
he annual number of disease cases prevented by vaccination has√
√ √
increased since 1980, due to both improved vaccine coverage and
increasing birth cohort size (Fig. 2). However, the number of deaths
prevented has decreased, because of declining case-fatality risks,
particularly for measles. In total, 2.3–5.7 million diseases cases and
10,000–26,000 deaths are estimated to have been prevented by EPI
in 1980–2010. The largest impact (in terms of deaths prevented
by vaccination) was  obtained when using model 12 for pertussis,
and using unadjusted surveillance data alone for other diseases.
The least impact was  obtained when using model 5 for polio, and
model 1 for other diseases.
LiST estimates even greater beneﬁt from EPI. According to LiST,
about 370,000 under-ﬁve deaths may  have been prevented by two
EPI vaccines (measles and pertussis), primarily through preven-
tion of measles mortality. This is mainly because LiST estimates of
mortality for measles (based on WHO  estimates) are about 70–200
times higher than those estimated from adjusted surveillance data,
although estimates for pertussis are similar. However, the propor-
tionate reduction in the number of deaths between 1980 and 2010
is similar: 99–100% and 97–100% for measles and pertussis using
national data, compared to 96% and 83% using LiST. LiST suggests
that EPI may  have been responsible for around 15% of under-ﬁve
mortality decline in Vietnam since 1980, mainly due to measles vac-
cination. Results for all four diseases are shown in Table 2, together
with corresponding ﬁgures using LiST.
The cost of EPI over 15 years (1996–2010) is estimated at $154.5
million, consisting of $41.8 million for routine DPT, $28.3 million
for polio, $8.6 million for ﬁrst measles dose, $5.41 million for sec-
ond measles dose, $0.25 million for DPT campaigns, $46.8 million
for polio campaigns and $23.4 million for measles campaigns (see
Appendix A.7 for costs disaggregated by year). Using the lowest
estimate of the number of deaths prevented in 1996–2010 (9400
deaths), EPI cost $27,000 per life saved. Since costs are only avail-
able for half time period 1980–2010 over which deaths prevented
are estimated, we use half the much higher estimate of deaths pre-
vented in 1980–2010 according to LiST (half of 370,000 deaths). This
suggests that EPI only cost $1000 per life saved. Indeed EPI may  be
even more cost-effective than suggested here, and may  even be net
cost-saving, as neither estimate incorporates cost savings to the
health sector due to reduced treatment. Furthermore, almost half
the cost of EPI was spent on polio vaccination, whose main aim is
not mortality prevention.
4. DiscussionWe have used two methods to assess the impact of EPI on disease
incidence and mortality in Vietnam since 1980. Statistical anal-
ysis of national surveillance data suggests that up to 5.7 million
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ot  be calculated as polio had been eliminated by then.
isease cases and 26,000 deaths may  have been prevented by EPI.
 signiﬁcant temporal association between disease incidence and
accine coverage was found. Using LiST suggests that about 370,000
eaths may  have been prevented by two EPI vaccines (measles and
able 2
stimated EPI impact on cases and deaths due to measles, pertussis, diphtheria and polio
Measles Pertussis 
Low1 High1 Low1 High1
Using national surveillance data
Cases 1980 40,000 110,000 35000 78,000 
Cases 2010 2900 15,000 0 6900 
Deaths 1980 170 460 26 59 
Deaths 2010 0.85 4.4 0 2.1 
Deaths per 1000 cases 1980 4.2 4.2 0.76 0.76
Deaths per 1000 cases 2010 0.3 0.3 0.31 0.31
Vaccine prevented cases
1980–2010
1.2 3.1 1 2.4 
Vaccine prevented deaths
1980–20102
1900 5300 3700 8200 
Vaccine prevented cases
1996–20103
0.81 2.2 0.77 1.7 
Vaccine prevented deaths
1996 - 20102,3
380 1100 3300 7300 
%  reduction in cases due to
vaccination (2010 vs.
1980)
93 86 100 91 
%  reduction in deaths due
to vaccination (2010 vs.
1980)
99 99 100 96 
Using LiST
Deaths 1980 23,000 300 
Annual deaths 2000–2010 1000 50 
Vaccine prevented deaths
1980–2010
366,000 5000 
%  reduction in deaths due
to vaccination (1980 to
2000–2010)
96% 83% 
“Low” and “high” represent ﬁgures from the highest and lowest results (in terms of dise
Calculated as number of cases prevented by vaccination in each year × case-fatality risk
Vaccine impact for 1996–2010 only was used to calculate cost-effectiveness, since ﬁnanased on notiﬁed cases and deaths. The case-fatality risk for polio after 1996 could
pertussis). Cost-effectiveness analysis using ﬁnancial data suggests
that EPI costs around $1000–$27,000 per death prevented.
The lower end of the range for cost-effectiveness, based on
LiST estimates of mortality, is close to a Disease Control Priorities
.
Diptheria Polio Total
Low1 High1 Low1 High1 Low1 High1
1300 3900 580 1800 76,880 19,3700
6 610 0 540 2906 23,050
150 440 22 70 368 1029
0.11 12 0 12 0.96 30.5
 110 110 38 38 0.0048 0.0053
 19 19 23 23 0.00033 0.0013
0.038 0.11 0.019 0.058 2.257 5.668
2800 8800 960 3200 9360 25,500
0.028 0.08 0.017 0.045 1.625 4.025
1500 4400 600 1600 5780 14,400
100 85 100 71 96% 88%
100 97 100 82 87% 96%
26,800
1250
411,000
95%
ase impact) of twelve linear regression models used.
 in the same year.
cial costs were only available starting from 1996.
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etwork estimate for East Asia and the Paciﬁc of EPI costing $434
er death prevented [3]. This is unsurprising since both LiST and the
isease Control Priorities Network estimate vaccine-preventable
ortality based on WHO  cause-speciﬁc mortality ﬁgures. However,
he cost-effectiveness ratio estimated using national surveillance
ata is much greater. This is because LiST estimates more than ten
imes the number of measles deaths prevented by EPI compared to
ational surveillance data, although the proportionate reduction in
eaths is much more similar between the two approaches.
The difference in absolute numbers may  stem from under-
scertainment of measles deaths in national surveillance data due
o either misattribution of measles deaths to other causes, orI from 1980 to 2010 based on models ﬁtted to national surveillance data.
measles patients not seeking health care. Furthermore, if under-
ascertainment has decreased since 1980 (as may  be expected due
to improved surveillance and health care access) then the mag-
nitude of decline in measles deaths from 1980 to 2010 will be
underestimated.
To adjust for underascertainment, we use mumps  notiﬁcations
as a control variable to represent changes in infectious disease noti-
ﬁcations that are not related to vaccination. Mumps-containing
vaccines are not routinely administered in Vietnam; hence any
changes in notiﬁcations of mumps  cases must be due to the other
factors, which are assumed to equally affect other communicable
diseases. The control variable accounts for both (i) improvements
A e 33S (2015) A233–A239
i
a
w
t
A
w
o
d
ﬁ
d
c
h
a
t
d
n
c
R
t
n
h
e
t
p
l
4
p
a
w
o
r
t
t
i
u
t
1
a
m
c
o
p
t
t
r
h
p
t
e
c
o
i
o
H
v
(
p
a
a
t
i
m
Table 3
Two  approaches to retrospectively estimate the impact of a vaccination programme.
Surveillance based
estimation
Impact model based
estimation
Description Monitor cases and deaths
due to a disease both
before and during
vaccination
Model the likely reduction
in morbidity and/or
mortality based on disease
natural history and vaccine
effectiveness
Strengths Direct observation of
changes in incidence.
Hence able to capture
complex nonlinear effects
such as herd protection
Less affected by
surveillance biases
Limitations Affected by
underascertainment or
misattribution of
disease/deaths, as well as
changes in
morbidity/mortality due to
Estimated vaccine impact
is dependent on the order
in which interventions are
applied when there are
multiple interventions that
can affect disease incidence238 M. Jit et al. / Vaccin
n disease ascertainment which may  have caused incidence to rise,
nd (ii) changes in disease risk factors (such as improved hygiene)
hich may  have caused incidence to fall. There was a decreasing
rend in mumps  incidence between 1980 and around 1990 (see
ppendix A.2), suggesting that declines in disease risk factors out-
eighed the effect of improved ascertainment until the latter part
f the study period. This means that mumps-adjusted disease inci-
ence is higher than unadjusted incidence in our model for the
rst part of the study period. Unfortunately, it is not possible to
isentangle the individual effects of both changes through a single
ontrol variable. Another limitation is that this method would not
ave captured changes in diphtheria, pertussis, measles or polio
scertainment that did not affect mumps. For example, case ascer-
ainment for measles may  have improved more than for mumps,
ue to the regional focus on measles elimination [8].
Several studies have examined underascertainment in Viet-
amese surveillance sources. A household study in Bavi District
ompared mortality recorded through the Commune Population
egistration System (CPRS) in 1999–2000 with that estimated using
hree other methods (re-census, communal death registration and
eighbourhood surveys) [9]. This suggested that the CPRS may
ave missed around 19% of deaths, particularly in infant and the
lderly, but did not examine deaths that may  have been assigned
o the wrong cause. A cross-sectional survey in 2008/2009 com-
aring surveillance case reports with cases recorded in health care
ogbooks of commune health stations found a shortfall of 61.3%,
7.5% and 56.3% for inﬂuenza-like illness, pneumonia and severe
neumonia, respectively [10]. Our own estimates using mumps  as
 control variable suggests that in 1999, 48% more mumps  cases
ere missed compared to 2010.
A second potential cause of the difference between the analysis
f surveillance data and LiST is that the former analysis adjusts for
eductions in incidence and mortality that may  have occurred due
o non-vaccine related factors such as health care access, popula-
ion structure, overall health, crowding and sanitation. Reduction in
nfectious disease incidence due to non-vaccine causes is captured
sing the adjustment factor based on mumps  notiﬁcations. Indeed,
he incidence of mumps  notiﬁcations decreased between 1980 and
990, possibly due to improvements in health, before increasing
fter 1990, possibly due to improved surveillance. Reduction in
ortality due to non-vaccine causes is captured by assuming that
ase-fatality risks in a particular year would still hold in the absence
f these non-vaccine factors, even if vaccination had not taken
lace, and vaccination would only reduce the number of cases of
he disease.
One limitation of our statistical analysis of surveillance data is
hat it relates vaccine coverage to disease incidence using linear
egression models that do not capture non-linear effects such as
erd protection [7]. The models adequately describe the overall
attern of disease decline as coverage increases from zero to close
o 100% since herd effects are minimal at both extremes of the cov-
rage range. However, outbreaks due to short-term ﬂuctuations in
overage are less well captured.
LiST takes a different approach. LiST is a multi-cause model
f mortality, which captures the interactions between different
nterventions that prevent or allow deaths to occur. This relies
n WHO  estimates of mortality using natural history models [11].
owever, LiST assigns mortality reductions due to preventive inter-
entions (such as vaccination) before therapeutic interventions
such as nutritional supplementation and improved access to hos-
ital care). For instance, the impact of measles vaccination is
pplied to measles mortality ﬁrst, and the effect of vitamin A ther-
py on measles mortality is only applied to the measles deaths
hat remain after the application of vaccination. Consequently, LiST
s likely to assign a greater proportion of the decline in measles
ortality since 1980 to vaccination compared to the analysis ofnon-vaccine related causes and mortality (such as
vaccination and treatment)
surveillance data. Hence the difference in the two model estimates
may  be due to under-ascertainment in national data, overestima-
tion by LiST, or a combination of both.
These methodologies can be used in other settings with vaccine-
preventable disease surveillance to retrospectively estimate the
impact of EPI. The regression method can be used in any setting
with (i) an adequate time series of case and death notiﬁcations, and
(ii) vaccine coverage for both diseases prevented by EPI vaccines as
well as another disease (such as mumps) not affected by existing
vaccines. LiST has also been used in other settings. For example,
one analysis showed that 11% of recent child mortality reduction
in Niger is likely due to vaccines [12]. LiST has also been used to
prospectively estimate the potential impact of introducing vaccines
or accelerating broader vaccine introduction [13,14].
The difference in deaths averted between the two methods in
our analysis is very large, even after adjusting surveillance data for
under-ascertainment. This highlights the importance of using mul-
tiple methods to estimate vaccine impact when directly observed
and actively reported data are not available, as is the case in
most low and middle income countries. Having multiple estimates
allows triangulation of a likely range in which the true value of
deaths averted is likely to lie. However, further investigation into
the extent of under-ascertainment in surveillance data and the
importance of non-vaccine causes of mortality decline is needed
in order to determine which of the two  estimates is closest to the
truth.
Despite these differences, it is highly reassuring that the broad
conclusion from both approaches is the same: Vietnam’s EPI has
made a substantial impact on mortality and is very likely to be cost-
effective, even under conservative assumptions. As more countries
graduate from Gavi funding and rely on internal resources, impact
and economic analyses of national vaccination programmes such as
EPI are likely to become increasingly important. Furthermore, our
methodology suggests that both surveillance and modelling play
important and complementary roles in such estimates (Table 3).
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